November 11, 2026 · Regulatory Affairs
The US Hemp Ban: What Changes 11 December 2026 for Canadian Suppliers
By Mussarat Fatima

For three years, Canadian companies have shipped hemp-derived CBD and low-dose THC ingredients into the United States under a federal definition of hemp that most people treated as settled. That definition is about to change. On 2 September 2026, the United States enacted H.R. 6500, the Continuing Appropriations and Extensions Act, 2027. The law moves the effective date of sweeping new restrictions on hemp-derived THC products to 11 December 2026, and keeps a narrower set of synthetic cannabinoid restrictions on an earlier date, 12 November 2026.
For Canadian suppliers, this is not an abstract US policy debate. It decides whether a product can legally cross the border at all after these dates, how it must be tested and labelled, and whether US customers will keep their purchase orders open. This article explains what changes on each date, what the new federal definition of hemp actually says, and the concrete steps a Canadian exporter should take before 11 December 2026.
Executive summary
H.R. 6500 did not repeal the coming hemp restrictions. It delayed the main ones by about a month, from 12 November to 11 December 2026, and kept a carve-out that lets the United States restrict certain synthetic cannabinoids on the original 12 November date. The core change is a new, far tighter federal definition of hemp built around a 0.4 milligram total THC per container limit.
- Two dates: synthetic cannabinoid restrictions on 12 November 2026, and the main hemp definition change on 11 December 2026.
- New threshold: products above 0.4 milligrams of total THC per container are no longer federal hemp.
- No further delay signalled: a White House official reportedly committed to no extension past 11 December, though further legislative action is still possible.
- Canadian exposure: CBD ingredients, finished CBD goods, hemp beverages, and intoxicating hemp products sold into the US market are all in scope.
- Action window: use the weeks before 11 December to classify products, confirm testing, and plan reformulation or market exit.
What changed on 2 September 2026?
On 2 September 2026, President Donald Trump signed H.R. 6500 into law. The bill pushed the scheduled federal restrictions on hemp-derived THC products back from 12 November to 11 December 2026. It also kept a carve-out that allows restrictions on certain synthetic cannabinoids to take effect on 12 November. The underlying restrictions come from a provision enacted in the prior appropriations cycle that rewrites how the United States defines hemp.
Before this change, the 2018 Farm Bill defined hemp as Cannabis sativa L. with no more than 0.3 percent delta-9 THC by dry weight. That dry-weight test let a wide market of CBD products, THCA flower, and hemp-derived delta-8 and delta-9 edibles and beverages operate as federally legal hemp. The new provision replaces that framework with a per-container limit on total THC and a direct restriction on synthetic cannabinoids. H.R. 6500 did not undo that provision. It only moved the clock. Canada regulates industrial hemp under its own rules, so the US change affects the export market rather than domestic Canadian status.
The delay was contested. In the US Senate, an amendment to strip the delay was set aside, and the broader funding bill passed. Industry groups continue to seek further relief, but as things stand the 11 December 2026 date holds.
| Date | What takes effect | Primary impact |
|---|---|---|
| 12 November 2026 | Restrictions on certain synthetic cannabinoids not capable of being naturally produced by a Cannabis sativa L. plant | Fully synthetic and lab-converted cannabinoids lose federal hemp status first |
| 11 December 2026 | The revised federal definition of hemp, including the 0.4 mg total THC per container limit | Most hemp-derived THC and CBD products are reclassified if they exceed the limit |
What the new federal definition of hemp says
The new definition narrows federal hemp to products with no more than 0.4 milligrams of total THC per container. Total THC counts delta-9 THC and other intoxicating THC compounds, not just delta-9 by dry weight. A product that exceeds 0.4 milligrams of total THC per container, or that relies on restricted synthetic cannabinoids, is treated as marijuana under federal law, which is a Schedule I controlled substance.
This is a structural shift, not a tweak. A per-container limit measured in milligrams is far stricter than a 0.3 percent dry-weight test. A single gummy, a beverage, or a tincture that was comfortably compliant under the dry-weight standard can easily exceed 0.4 milligrams of total THC per container. For many intoxicating hemp products, there is no formulation that both delivers the intended effect and stays under the new limit.
Why 12 November still matters: the synthetic carve-out
H.R. 6500 kept a carve-out that lets the United States restrict synthetic cannabinoids on the earlier 12 November 2026 date. These are cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant, including fully synthetic compounds and some that are chemically converted or manufactured outside the plant. If a product depends on converted or synthesised cannabinoids, its exposure can begin a month before the main definition change.
This matters most for delta-8 THC and similar cannabinoids that are commonly produced by chemically converting CBD. Depending on how a cannabinoid is made and characterised, it may fall under the earlier synthetic restriction rather than waiting for the 11 December definition change. Suppliers of converted-cannabinoid ingredients should not assume they have until December. Our guidance on synthesized cannabinoids and your preventive control plan explains how Canadian rules treat these compounds.
Who this affects in Canada
Any Canadian company that sells hemp-derived products into the United States is affected: CBD isolate and distillate suppliers, finished CBD goods makers, hemp beverage producers, and businesses that sell intoxicating hemp edibles or vapes into US channels. Canadian ingredient suppliers face cancelled or paused US purchase orders, and finished-goods exporters face products that can no longer enter the US as hemp.
- CBD ingredient suppliers: isolate, distillate, and full-spectrum oil sold to US manufacturers.
- Finished CBD goods: tinctures, capsules, topicals, and gummies shipped to US retailers or direct to consumer.
- Hemp beverage makers: THC and CBD drinks that rely on hemp-derived cannabinoids.
- Converted-cannabinoid suppliers: delta-8 and similar products exposed to the earlier 12 November restriction.
- Contract manufacturers and co-packers: businesses whose US clients are reassessing their entire hemp portfolio.
What Canadian suppliers must do before 11 December 2026
Work in order: inventory the US-bound portfolio, classify each product against the new definition, confirm testing on a total-THC-per-container basis, decide on reformulation or exit, and document the plan. The goal is to know, product by product, whether each item can still enter the US after each date, and what you will do if it cannot.
- Build a product inventory. List every hemp-derived product and ingredient sold into the US, with its cannabinoid profile and the cannabinoid source (naturally extracted or converted and synthesised).
- Classify against both dates. For each item, decide whether it is exposed on 12 November (synthetic carve-out), on 11 December (0.4 mg total THC limit), or both.
- Re-test on the right basis. Confirm total THC per finished container, not percentage by dry weight. Use an accredited laboratory and keep the certificates of analysis.
- Decide: reformulate, repath, or exit. For products that fail, consider reformulating below the limit where feasible, moving them to a Canadian Natural Health Product or Cannabis Act pathway, or withdrawing them from the US market.
- Fix labels and claims. Remove hemp or federally-legal claims that will be false after the relevant date, and align labels with the market you will actually serve.
- Notify customers and document everything. Tell US customers which products change and when, and keep a written record of classification decisions and the evidence behind them.
| Product type | Likely status after the dates | Suggested action |
|---|---|---|
| Non-intoxicating CBD isolate, very low total THC | May remain compliant if under 0.4 mg total THC per container | Confirm with container-level testing and keep certificates of analysis |
| Full-spectrum CBD oil or gummies | At risk if total THC per container exceeds the limit | Re-test, reformulate to isolate-based, or exit the US market |
| Delta-8 and other converted cannabinoids | Exposed to the 12 November synthetic restriction | Plan an earlier exit or a Canadian pathway, and do not wait for December |
| Intoxicating hemp beverages and edibles | Likely reclassified as marijuana federally | Pivot to a Canadian cannabis pathway or compliant markets, and withdraw from the US hemp channel |
Compliance checklist
- Complete a full inventory of US-bound hemp-derived products and ingredients.
- Classify each product against the 12 November and 11 December 2026 dates.
- Re-test every product for total THC per finished container at an accredited laboratory.
- Identify products that rely on synthetic or converted cannabinoids.
- Decide reformulation, Canadian pathway, or US market exit for each failing product.
- Update labels, marketing claims, and specifications to match the market served.
- Issue written notices to US customers with dates and affected product codes.
- Retain certificates of analysis, classification decisions, and correspondence for your records.
- Review Canadian regulatory options for reformulated or redirected products, including the Natural Health Product and Cannabis licence pathways.
Common mistakes to avoid
- Reading current certificates of analysis against the old 0.3 percent dry-weight test instead of the new total-THC-per-container limit.
- Assuming all restrictions start on 11 December and missing the 12 November synthetic cannabinoid date.
- Treating delta-8 and other converted cannabinoids as ordinary hemp with a December deadline.
- Waiting for further federal relief instead of planning for the dates as they stand.
- Changing US labels without checking Canadian rules for the pathway you pivot to.
- Forgetting that individual US states set their own dates and limits, which may be stricter than the federal timeline.
Frequently asked questions
When does the US hemp ban take effect?
The main federal definition change takes effect on 11 December 2026. Restrictions on certain synthetic cannabinoids take effect earlier, on 12 November 2026. Both dates come from H.R. 6500, which was signed into law on 2 September 2026.
What is the new federal limit for hemp products?
Federal hemp is being redefined around a limit of 0.4 milligrams of total THC per container. Products above that limit, or that rely on restricted synthetic cannabinoids, are treated as marijuana under US federal law.
Can Canadian CBD products still be sold in the United States after the ban?
Some may, if they stay under 0.4 milligrams of total THC per container and do not rely on restricted synthetic cannabinoids. Each product must be tested on a per-container, total-THC basis and classified individually. Products that exceed the limit lose federal hemp status.
Does the ban apply to delta-8 THC?
Delta-8 and other cannabinoids commonly made by converting CBD can fall under the synthetic cannabinoid carve-out, which takes effect on 12 November 2026. That can put converted-cannabinoid products at risk earlier than the main 11 December date.
Will there be another delay?
A White House official reportedly committed to no further extension past 11 December 2026. Industry groups continue to seek relief, and additional legislation is possible, but suppliers should plan for the dates as they currently stand rather than count on a delay.
What are the options for products that no longer qualify?
Depending on the product, options include reformulating below the new limit, moving the product to a Canadian Natural Health Product or Cannabis Act pathway, redirecting it to compliant markets, or withdrawing it from the US hemp channel. Each option has its own regulatory requirements, which is where a structured review helps.
How MFLRC can help
MFLRC helps Canadian hemp, CBD, and cannabis businesses turn a regulatory deadline into a controlled plan. We run a portfolio risk triage to tell you, product by product, what changes on 12 November and 11 December 2026, and what the options are. Our team supports regulatory pathway strategy under the Cannabis Act and the Natural Health Products Regulations, export compliance reviews, and label and formulation review so claims match the market served. We also track parallel shifts such as the EU hemp rules and Health Canada's industrial hemp consultation, so an export plan holds up across markets. Where products need to move to a Canadian pathway, we help with licensing, SOP development, and the quality systems that pathway requires.
Conclusion
The US hemp market that Canadian suppliers have relied on is being redrawn by two dates. On 12 November 2026, synthetic cannabinoid restrictions begin. On 11 December 2026, a new federal definition of hemp built around a 0.4 milligram total THC per container limit takes effect, and products that exceed it are treated as marijuana. The companies that come through this well will be the ones that classified their portfolio early, tested on the right basis, and decided in advance how each product would reach its market. The window to do that work is now, not in December.
Sources and references
Downloadable Resource
US Hemp Two-Date Transition Checklist
A one-page checklist that walks Canadian hemp and CBD exporters through both the 12 November and 11 December 2026 positions: product classification, total-THC testing against the 0.4 mg per container limit, label and COA remediation, and market-exit or Canadian-pathway decisions.
File: MFLRC-US-Hemp-Two-Date-Transition-Checklist.pdf
Share with others
Tags
